Actualités
Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.
If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following ...
After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...
Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...
Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...
In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...
(Bloomberg) -- Sarepta Therapeutics Inc. shares soared after the company said it was cutting more than a third of its workforce and that its gene therapy for a fatal muscle disorder would stay on the ...
A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...
Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.
CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a $5.7 billion market cap biotechnology company, announced that clinical trials for its gene therapy ELEVIDYS will resume following a ...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) announced that it has entered into a licensing agreement with Roche (OTC: RHHBY) related to its lead gene therapy candidate, SRP-9001, for treating ...
Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed.
Certains résultats ont été masqués, car ils peuvent vous être inaccessibles.
Afficher les résultats inaccessibles